Title

Immunologic and Virologic Response to Highly Active Antiretroviral Therapy in the Multicenter AIDS Cohort Study

Authors

Traci Yamashita, Johns Hopkins School of Hygiene and Public Health
John Phair, Northwestern University Medical School
A. Muñoz, Johns Hopkins University
Joseph Margolick, Johns Hopkins School of Hygiene and Public Health
Roger Detels, University of California - Los Angeles
Stephen J. O'Brien, National Cancer Institute at FrederickFollow
John Mellors, University of Pittsburgh
Steven M. Wolinsky, Northwestern University Medical School
Lisa Jacobson, Johns Hopkins School of Hygiene and Public Health

Document Type

Article

Publication Date

4-13-2001

Publication Title

AIDS

Keywords

HIV-1, Highly active antiretroviral therapy, Prior antiretroviral experience, Genetic markers, Immunologic response, Virologic response

ISSN

0269-9370

Volume

15

Issue/No.

6

First Page

735

Last Page

746

Abstract

Objectives: To evaluate prior antiretroviral therapy experience and host characteristics as determinants of immunologic and virologic response to highly active antiretroviral therapy (HAART).

Methods: We studied 397 men from the Multicenter AIDS Cohort Study (MACS) who initiated HAART between October 1995 and March 1999. CD4 cell count and HIV-1 RNA responses to HAART were measured at the first visit following HAART (short-term) and extending from the first visit to approximately 33 months after HAART (long-term). Prior antiretroviral experience was classified into three groups based on antiretroviral therapy use during the 5 years prior to HAART. Age, race and host genetic characteristics also were assessed for their effects on treatment response.

Results: Better short- and long-term CD4 cell and HIV-1 RNA responses were observed in the treatment-naive users. Intermittently and consistently experienced users did not significantly differ in response. Whereas race did not independently affect response, among those initiating HAART with > 400 × 10⁶ CD4 cells/l, younger age and the Δ32 CCR5 genotype were associated with a better short-term CD4 cell response. There was a suggestion that having the protective CCR5 genotype also was associated with a better long-term CD4 cell response.

Conclusion: Immunologic and virologic response to HAART was stronger in individuals who had no prior experience with the antiretroviral therapy agents subsequently included in their initial HAART regimen. Age, level of immune competence and immunogenetics appeared to play a role in the subsequent immune reconstitution following use of highly effective HIV therapy.

Comments

©2001 Lippincott Williams & Wilkins

Additional Comments

National Institute of Allergy and Infectious Diseases grant #s: UO1-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-AI-35043, UO1-AI-37984; UO1-AI-35039; UO1-AI-35040, UO1-AI-37613; UO1-AI-35041

NSUWorks Citation

Yamashita, Traci; John Phair; A. Muñoz; Joseph Margolick; Roger Detels; Stephen J. O'Brien; John Mellors; Steven M. Wolinsky; and Lisa Jacobson. 2001. "Immunologic and Virologic Response to Highly Active Antiretroviral Therapy in the Multicenter AIDS Cohort Study." AIDS 15, (6): 735-746. https://nsuworks.nova.edu/cnso_bio_facarticles/627

ORCID ID

0000-0001-7353-8301

ResearcherID

N-1726-2015